|
|
|
Insider
Information: |
Baker Julian |
Relationship: |
|
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
36 |
|
Direct
Shares |
1,043,405 |
|
Indirect Shares
|
249,901,274 |
|
|
Direct
Value |
$79,577,343 |
|
|
Indirect Value
|
$17,327,382,345 |
|
|
Total
Shares |
250,944,679 |
|
|
Total
Value |
$17,406,959,688 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
5
|
2
|
Stock
price went up :
|
0
|
2
|
Stock
price went down : |
5
|
0
|
|
|
|
Gain/Loss Ratio : |
-5.0
|
2.0
|
Percentage
Gain/Loss : |
-30.6%
|
6.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Synageva BioPharma Corp |
GEVA |
10% Owner |
2003-09-26 |
0 |
2011-11-02 |
144,082 |
Premium* |
|
Innoviva Inc |
INVA |
Director |
2005-12-13 |
0 |
2004-10-04 |
33,839 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2004-10-13 |
0 |
2011-06-30 |
4,045,398 |
Premium* |
|
Incyte Corp |
INCY |
|
2024-06-28 |
559,963 |
2024-06-28 |
28,216,552 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2019-08-29 |
0 |
2019-08-29 |
9,262,659 |
Premium* |
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
2009-01-23 |
0 |
2009-01-23 |
2,258 |
Premium* |
|
Viropharma Inc |
VPHM |
10% Owner |
|
0 |
2011-12-14 |
9,840,469 |
Premium* |
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2009-10-19 |
5,264,782 |
Premium* |
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2012-01-27 |
0 |
Premium* |
|
Pharmacyclics Inc |
PCYC |
10% Owner |
2011-08-22 |
0 |
2012-02-10 |
557,211 |
Premium* |
|
XOMA Corporation |
XOMA |
Former 10% owner |
|
0 |
2015-07-22 |
90,538 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
3,540,015 |
Premium* |
|
Neurogene |
NGNE |
Director |
2020-07-07 |
4,520 |
2020-07-07 |
3,501,691 |
Premium* |
|
Acadia Pharmaceuticals Inc |
ACAD |
|
2024-05-29 |
205,752 |
2024-05-29 |
39,349,751 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
2018-03-28 |
0 |
2018-03-28 |
7,553,553 |
Premium* |
|
Aceragen, Inc |
ACGN |
10% Owner |
2019-07-01 |
43,858 |
2019-07-01 |
4,290,995 |
Premium* |
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
Former 10% owner |
2017-10-05 |
0 |
2017-10-05 |
1,878,242 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
2017-11-08 |
274 |
2017-11-08 |
35,999 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
2018-01-17 |
0 |
2018-01-19 |
58,131 |
Premium* |
|
Beigene Ltd |
BGNE |
|
2024-06-05 |
20,838 |
2024-06-05 |
10,694,996 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2021-05-14 |
46,557 |
2021-05-14 |
43,309,073 |
Premium* |
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2020-05-14 |
131,963 |
2020-05-14 |
7,940,623 |
Premium* |
|
Kiniksa Pharmaceuticals, Ltd. |
KNSA |
|
2024-06-05 |
29,680 |
2024-06-05 |
2,725,689 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2018-10-09 |
0 |
2021-09-30 |
13,526,726 |
Premium* |
|
Atreca Inc |
BCEL |
10% Owner |
2019-06-24 |
0 |
2019-06-24 |
3,223,030 |
Premium* |
|
Igm Biosciences, Inc. |
IGMS |
Director, 10% Owner |
2019-09-20 |
0 |
2021-01-27 |
2,895,306 |
Premium* |
|
Prelude Therapeutics Inc |
PRLD |
Director, 10% Owner |
|
0 |
2021-01-27 |
9,252,951 |
Premium* |
|
DBV Technologies SA |
DBVT |
Director, 10% Owner |
|
0 |
2021-01-01 |
4,286,038 |
Premium* |
|
Talis Biomedical Corp |
TLIS |
Director, 10% Owner |
|
0 |
2021-02-17 |
7,003,766 |
Premium* |
|
Aeglea Biotherapeutics, Inc. |
AGLE |
Director |
|
0 |
2021-02-23 |
3,410,106 |
Premium* |
|
Tscan Therapeutics, Inc. |
TCRX |
Director |
2021-07-20 |
0 |
2021-07-20 |
1,320,302 |
Premium* |
|
Entrada Therapeutics, Inc. |
TRDA |
10% Owner |
|
0 |
2021-12-14 |
4,704,419 |
Premium* |
|
Bicycle Therapeutics Ltd |
BCYC |
|
|
0 |
2024-06-17 |
8,636,006 |
Premium* |
|
Immunocore Holdings Adr |
IMCR |
|
|
0 |
2024-05-28 |
1,515,318 |
Premium* |
|
Madrigal Pharmaceuticals Inc |
MDGL |
|
2024-06-25 |
0 |
2024-06-25 |
1,794,831 |
Premium* |
|
Kymera Therapeutics, Inc. |
KYMR |
|
2024-08-20 |
0 |
2024-08-20 |
5,995,929 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
506 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 17 of 21
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
GHDX |
Genomic Health Inc |
Director |
|
2019-08-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
190,578 |
0 |
0 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2019-09-19 |
4 |
OE |
$0.01 |
$0 |
I/I |
1 |
8,374,936 |
0 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2019-09-20 |
4 |
B |
$16.00 |
$50,304,000 |
I/I |
3,144,000 |
2,883,204 |
2.25 |
- |
|
ACAD |
Acadia Pharmaceuticals In... |
Director |
|
2019-09-20 |
4 |
B |
$40.00 |
$62,500,000 |
I/I |
1,562,500 |
37,470,965 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2019-09-30 |
4 |
A |
$74.23 |
$54,039 |
I/I |
728 |
29,291,207 |
0 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2019-12-06 |
4 |
B |
$46.00 |
$87,499,958 |
I/I |
1,902,173 |
10,118,929 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2019-12-31 |
4 |
A |
$87.32 |
$55,186 |
I/I |
632 |
29,291,523 |
0 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2020-02-24 |
4 |
B |
$55.45 |
$4,093,553 |
I/I |
71,123 |
10,184,170 |
2.25 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2020-02-25 |
4 |
B |
$57.22 |
$11,937,248 |
I/I |
206,126 |
10,373,248 |
2.25 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2020-02-26 |
4 |
B |
$57.82 |
$5,799,441 |
I/I |
100,000 |
10,464,977 |
2.25 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Director |
|
2020-03-16 |
4 |
B |
$75.66 |
$20,894,753 |
I/I |
265,298 |
7,626,298 |
2.1 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2020-03-16 |
4 |
B |
$39.97 |
$4,180,977 |
I/I |
104,600 |
10,560,911 |
2.25 |
- |
|
ACAD |
Acadia Pharmaceuticals In... |
Director |
|
2020-03-16 |
4 |
B |
$31.19 |
$21,878,017 |
I/I |
694,303 |
38,107,749 |
2.25 |
- |
|
ACAD |
Acadia Pharmaceuticals In... |
Director |
|
2020-03-17 |
4 |
B |
$31.00 |
$7,218,907 |
I/I |
219,800 |
38,309,339 |
2.25 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2020-03-17 |
4 |
B |
$38.99 |
$389,850 |
I/I |
10,000 |
10,570,083 |
2.25 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Director |
|
2020-03-17 |
4 |
B |
$76.10 |
$7,836,585 |
I/I |
102,421 |
7,720,234 |
2.1 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Director |
|
2020-03-18 |
4 |
B |
$79.16 |
$4,059,792 |
I/I |
50,902 |
7,766,918 |
2.1 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Director |
|
2020-03-18 |
4 |
B |
$81.09 |
$6,673,935 |
I/I |
81,379 |
7,841,556 |
2.1 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2020-03-18 |
4 |
B |
$36.69 |
$1,322,977 |
I/I |
35,400 |
10,602,550 |
2.25 |
- |
|
ACAD |
Acadia Pharmaceuticals In... |
Director |
|
2020-03-18 |
4 |
B |
$31.94 |
$4,555,101 |
I/I |
135,897 |
38,433,977 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2020-03-31 |
4 |
A |
$73.23 |
$57,412 |
I/I |
784 |
29,291,915 |
0 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2020-04-01 |
4 |
A |
$0.00 |
$0 |
I/I |
446 |
2,883,427 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2020-04-23 |
4 |
OE |
$12.76 |
$446,600 |
I/I |
35,000 |
45,860,149 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2020-04-28 |
4 |
OE |
$13.34 |
$533,600 |
I/I |
40,000 |
29,311,915 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2020-05-06 |
4 |
S |
$164.06 |
$64,379,473 |
I/I |
(390,072) |
45,502,996 |
0 |
- |
|
506 Records found
|
|
Page 17 of 21 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|